Understanding LipiFlow Thermal Pulsation

Feb 07, 2024

misc image

Understanding LipiFlow Thermal Pulsation

Dry Eye Disease and Meibomian Gland Dysfunction (MGD) are among the most common ocular conditions affecting tens of millions of patients in the United States and many more worldwide. Ocular symptoms such as dryness, irritation, redness, and blurred vision can significantly impact daily life and productivity. While temporary relief is possible with over-the-counter drops, addressing the root cause requires more advanced treatment. Enter LipiFlow Thermal Pulsation – a groundbreaking office-based procedure that offers hope and relief for those suffering from chronic dry eye conditions.

Understanding Dry Eye and Meibomian Gland Dysfunction (MGD)

Dry eye disease occurs when tears are insufficient to lubricate the eye adequately, leading to discomfort and potential damage to the ocular surface. Meibomian glands, located in the eyelids, produce the lipid component of tears, which helps prevent evaporation and maintains tear film stability. In MGD, these glands become blocked or dysfunctional, resulting in poor tear quality and instability.

The Role of LipiFlow Thermal Pulsation

LipiFlow Thermal Pulsation is a cutting-edge procedure designed to address the root cause of dry eye and MGD by targeting the meibomian glands directly. The treatment utilizes a combination of heat and gentle pressure to unclog blocked glands and facilitate the secretion of healthy lipids into the tear film. Here's how LipiFlow works:

1. Patient Preparation: Before the procedure, the patient's eyes are examined to assess the severity of dry eye symptoms. Objective tests are also performed such as tear film stability (TBUT), gland quality (meibum flow), and infrared imaging of the gland (meibography) to confirm the diagnosis of MGD.  Once the patient is ready for Lipiflow, anesthetic eye drops are applied to ensure comfort during the treatment (most patients refer to Lipiflow as an 'Eyelid massage treatment'.

2. LipiFlow Device Application: A specialized eyepiece containing a disposable activator is placed over the eye. The activator delivers controlled and sustained heat to the inner eyelid while simultaneously applying gentle pressure to the outer lid. This combination of heat and pressure helps liquefy and express the stagnant gland secretions.

3. Precise Treatment Duration: The LipiFlow procedure typically takes about 12 minutes per eye (both eyes are commonly treated at the same time). During this time, the device administers targeted thermal pulsations to the meibomian glands, effectively clearing blockages and restoring gland function.

4. Comfortable and Non-Invasive: LipiFlow treatment is well-tolerated by most patients and is performed in the comfort of our office. The procedure requires no incisions or anesthesia beyond topical numbing eye drops.

Benefits of LipiFlow Thermal Pulsation

  • Long-Term Relief: By addressing the root cause of dry eye and MGD, LipiFlow offers lasting relief from symptoms such as dryness, burning, and irritation.
  • Improved Tear Film Quality: Restoring the balance of lipids in the tear film enhances its stability and prevents rapid evaporation, leading to clearer vision and reduced discomfort.
  • Enhanced Meibomian Gland Function: LipiFlow helps revive and rejuvenate meibomian glands, promoting optimal tear production and ocular surface health.
  • Minimal Discomfort: Patients report minimal discomfort during and after the procedure, with many experiencing immediate improvement in symptoms.

Is LipiFlow Right for You?

LipiFlow Thermal Pulsation is suitable for patients diagnosed with dry eye disease and MGD who have not responded adequately to conventional treatments like artificial tears and warm compresses. However, it's essential to consult with an eye care professional to determine if LipiFlow is the right option for your specific condition and needs.

LipiFlow Thermal Pulsation represents a significant advancement in the management of dry eye disease and Meibomian Gland Dysfunction. By targeting the underlying cause of these conditions and restoring normal gland function, LipiFlow offers patients a renewed sense of comfort and clarity. If you're tired of living with dry, irritated eyes, it may be time to explore the benefits of LipiFlow with your eye care provider.

Remember, healthy eyes are essential for a vibrant life. Don't let dry eye symptoms hold you back – discover the transformative potential of LipiFlow Thermal Pulsation today.

Schedule your dry eye consult or Lipiflow session today.


Compiled List of Peer-Reviewed Literature on LipiFlow:

1) Narang P, Donthineni PR, D'Souza S, Basu S. Evaporative dry eye disease due to meibomian gland dysfunction: Preferred practice pattern guidelines for diagnosis and treatment. Indian J Ophthalmol. 2023 Apr;71(4):1348-1356.

2) Pucker, Andrew D; Rueff, Erin; Ngo, William; Tichenor, Anna A; Conto, John E.
LipiFlow for the treatment of dry eye disease. Cochrane Database of Systematic Reviews. 2022:12

3) Starr CE, Gupta PK, Farid M, Beckman K, Chan CC, Yeu E, Gomes J, Ayers BD, Berdahl JP, Holland EJ, Kim T, Mah FS, the ASCRS Corneal Clinical Committee.
An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019;45:669-684

4) Amano S. Meibomian Gland Dysfunction: Recent Progress Worldwide and in Japan. Inves Ophthalmol Vis Sci. 2018;59:DES87-DES93

5) Geerling G, Baudouin C, Aragona P, Rolando M, Boboridis KG, Benitez-Del-Castillo JM, Akova YA, Merayo-Lloves J, Labetoulle M, Steinhoff M, Messmer EM.
Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocul Surf. 2017; 15(2):179-192

6) Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hild RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Wolffsohn JS, Craig JP. TFOS DEWS II Management and Therapy Report. Ocular Surface. 2017;15(3):575-628

7) Hu J, Zhu S, Liu X. Efficacy and safety of a vectored thermal pulsation system (LipiFlowTM) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol.
2022 Jan;260(1):25-39.

8) Pang SP, Chen YT, Tam KW, Lin IC, Loh EW. Efficacy of Vectored Thermal Pulsation and Warm Compress Treatments in Meibomian Gland Dysfunction: A Meta-Analysis of Randomized Controlled Trials. Cornea. 2019;38(6):690-697

9) M W Beining, M Magno, E Moschowits, J Olafsson, J Vehof, D A Dartt, T P Utheim.
In-office thermal systems for the treatment of dry eye disease. Surv Ophthalmol. 2022: 67(5);1405-1418

10) Elisabeth M Messmer. Pathophysiology of dry eye disease and novel therapeutic targets. Exp Eye Res. 2022 Jan 22

11) Arita R, Fukuoka S. Non-pharmaceutical treatment options for meibomian gland dysfunction. Clin Exp Optom. 2020 doi: 10.1111/cxo.13035

12) Valencia-Nieto L, Novo-Diez A, Blanco-Vázquez M, López-Miguel A.
Therapeutic Instruments Targeting Meibomian Gland Dysfunction. Ophthalmol Ther. 2020 Sep 24. doi: 10.1007/s40123-020-00304-3.

13) Villani E, Marelli L, Dellavalle A, Serafino M, Nucci P. Latest evidences on meibomian gland dysfunction diagnosis and management. Ocul Surf. 2020 Sep 12;18(4):871-892.

14) Lam PY, Shih KC, Fong PY, Chan TCY, Ng AL, Jhanji V, Tong L. A Review on Evidence-Based Treatments for Meibomian Gland Dysfunction. Eye Contact Lens. 2020 Jan;46(1):3-16.

15) Herbaut A, Liang H, Denoyer A, Baudouin C, Labbé A. Tear film analysis and evaluation of optical quality: A review of the literature. J Fr Ophtalmol. 2019 Feb;42(2):e21-e35.

16) Ruan F, Jie Y. Emerging Strategies for the Treatment of Meibomian Gland Dysfunction. Zhonghua Yan Ke Za Zhi. 2019; 55(6): 465-468

17) Sabeti S, Kheirkhah A, Yin J, Dana R. Management of Meibomian Gland Dysfunction: A Review. Surv Ophthalmol. 2019 pii: S0039-6257(19)30253-X

18) Yu T, Hong J. Current and emerging treatment options for meibomian gland dysfunction. Chinese Journal of Experimental Ophthalmology. 2018;36(2):150-155

19) Downie LE, Craig JP. Tear film evaluation and management in soft contact lens wear: a systematic approach. Clin Exp Optom. 2017;100:438-58

20) Mandal P, Khan MA, Shah S. Drugs- Do we need them? Applications of non-pharmaceutical therapy in anterior eye disease. A review. Contact Lens and Anterior Eye. 2017; 40(6):360-366

21) Nassiri N, Zhou XY, Rodriguez Torres Y, Meyer Z, Beyer MA, Mehregan CA, Vellaichamy G, Chungfat N, Hwang FS. Current and emerging therapy of dry eye disease. Part B: non-pharmacological modalities. Expert Review of Ophthalmology. 2017;12(4):299-312

22) Thulasi P, Djalilian AR. Update in Current Diagnostics and Therapeutics of Dry Eye Disease. Ophthalmology. 2017;124(11 Supplement):S27-S33

23) Sarezky D, Massaro-Giordano M, Bunya VY. Novel Diagnostics and Therapeutics in Dry Eye Disease. Advances in Ophthalmology and Optometry. 2016;1(1):1-20

24) Blackie CA, Carlson AN, Korb DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Curr Opin Ophthalmol. 2015;26(4): 306-313

25) Duncan K, Jeng BH. Medical management of blepharitis. Curr Opin Ophthalmol. 2015 Jul;26(4):289-94.

26) Thode AR1, Latkany RA. Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD). Drugs. 2015 Jul;75(11):1177-85

27) Qiao J, Yan Xiaoming. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1797-1803

28) Mencucci R, Mercuri S, Cennamo M, Morelli A, Favuzza E. Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. J Cataract Refract Surg. 2022;49(4):423-429

29) Meng, Zhu, Xiaoran Chu, Chen Zhang, Hui Liu, Ruibo Yang, Yue Huang, Shaozhen Zhao. Efficacy and Safety evaluation of a single thermal pulsation system treatment (LipiFlow) on meibomian gland dysfunction: a randomized controlled clinical trial. Int Ophthalmol. 2022:1-10

30) Wesley G, Bickle K, Downing J, Fisher B, Greene B, Heinrich C, Kading D, Kannarr S, Miller J, Modi S, Ludwick D, Tauber J, Srinivasan S, Manoj V. Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study. Optom Vis Sci. 2022 Apr 1;99(4):323-332

31) Li S, Yang K, Wang J, Li S, Zhu L, Feng J, Tian L, Jie Y. Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients. Ophthalmol Ther. 2022 Feb;11(1):261-270.

32) Gupta PK, Holland EJ, Hovanesian J, Loh J, Jackson MA, Karpecki PM, Dhamdhere K. TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial. Cornea. 2022 Apr 1;41(4):417-426.

33) Park J, Yoo YS, Shin K, Han G, Arita R, Lim DH, Chung TY. Effects of Lipiflow Treatment Prior to Cataract Surgery: A Prospective, Randomized, Controlled Study. Am J Ophthalmol. 2021 Oct;230:264-275.

34) Zhao Y, Li J, Xue K, Xie J, Xie G, Gu S, Zhao Y. Preoperative Management of MGD with Vectored Thermal Pulsation before Cataract Surgery: A Prospective, Controlled Clinical Trial. Semin Ophthalmol. 2021 Feb 15:1-7.

35) Ambaw YA, Fuchs D, Raida M, Mazengia NT, Torta F, Wheelock CE, Wenk MR, Tong L. Changes of tear lipid mediators after eyelid warming or thermopulsation treatment for meibomian gland dysfunction. Prostaglandins Other Lipid Mediat. 2020 Dec;151:1064-74.

36) Kasetsuwan N, Suwajanakorn D, Tantipat C, Reinprayoon U. The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial. Clinical Ophthalmology. 2020;14:2891-2902

37) Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. Clinical Ophthalmology. 2020;14:405-18

38) Tauber J. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction. Cornea. 2020;39(4):403-07

39) Blackie CA, Coleman CA, Nichols KK, Jones L, Chen PQ, Melton R, Kading DL, O'Dell LE, Srinivasa S. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. Clin Ophthalmol. 2018;12:169-183

40) He JZ, Zhong M. Comparative study between the Meibomian pulsation system and the warm compress treatment for MGD. Guoji Yanke Zazhi (Int Eye Sci). 2018;18(7):1324-28 (Chinese)

41) Hagen KB, Bedi R, Blackie CA, Christenson-Akagi KJ. Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clin Ophthalmol. 2018;12:161-168.

42) Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016;10: 1385-1396.

43) Baumann A, Cochener B. Meibomian gland dysfunction: a comparative study of modern treatments. J Fr Ophtalmol. 2014;37(4):303-312 [French]

44) Finis D, Hayajneh J, Konig C, Borrelli M, Schrader S, Geerling G. Evaluation of an automated thermodynamic treatment (LipiFlow(R)) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf. 2014; 12(2):146-154.

45) Finis D, Konig C, Hayajneh J, Borrelli M, Schrader S, Geerling G. Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy. Cornea. 2014;33(12):1265-1270

46) Lane SS, DuBiner HB, Epstein RJ, Ernest PH, Greiner JV, Hardten DR, Holland EJ, Lemp MA, McDonald JE, Silbert DI, Blackie CA, Stevens CA, Bedi R. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012;31(4):396-404.